Latest News

The target enrollment goal has been reached in the phase 3 BiPASS study, evaluating PSMA-PET plus MRI for prostate cancer detection.

Routine cardiovascular specialist referral improved cholesterol control in patients with prostate cancer but did not reduce cardiovascular events.

LUGPA CEO Celeste Kirschner, CAE, MHSA, outlines the association's top 2027 priorities: fee schedule reform, site-neutral payments, prior authorization, and practice consolidation.

Martin Schoen, MD, PhD, discusses factors guiding ARPI selection in prostate cancer and how real-world evidence can help inform treatment decisions.

Closing racial disparities in prostate cancer requires meeting men in barbershops, churches, and community screenings—not just clinics, according to Justin Cohen, MD.

A recap of the FDA submissions and regulatory decisions in urology from August 2026.

Prof Declan Murphy discusses PROTEUS pathologic responses with apalutamide plus ADT and their implications for future treatment strategies.

In this Q&A, Zachary Feuer, MD, discusses the implementation of a telehealth-based rapid access program for evaluating men with an elevated PSA.

Timothy D. McClure, MD, discusses 2-year PRESERVE trial safety data and 12-month AUA findings linking prostate size to IPSS improvement after focal IRE.

The FDA has granted clearance to a phase 1 trial of ADI-212, a PSMA-targeted, gene-edited, armored cell therapy candidate under development for mCRPC.

University of Florida urology chiefs Miranda Eubank, MD; Trisha Nguyen, MD; and Jordan Matthews-Smith, MD, reflect on residency milestones, mentorship, community, and lessons learned along the way.

This FAQ outlines what the State of Men's Health Act would do, how a federal Office of Men’s Health could affect research and clinical care, and what urologists can do to support the effort.

Emanuele Crupi, MD, discusses prospective data supporting GemFLP as a benchmark for treatment of advanced urachal and non-urachal urinary tract adenocarcinomas.